Unicycive Therapeutics Inc Total Liabilities
Unicycive Therapeutics Inc total liabilities. Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) has total liabilities worth $18.76 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check UNCY cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Unicycive Therapeutics Inc (2018–2025)
Total liabilities of Unicycive Therapeutics Inc from 2018 to 2025. This chart illustrates how Unicycive Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Unicycive Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Unicycive Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cettire Ltd
AU:CTT
|
Australia | AU$88.51 Million |
|
GCT Semiconductor Holding Inc
NYSE:GCTS
|
USA | $96.31 Million |
|
Powercell Sweden
ST:PCELL
|
Sweden | Skr266.19 Million |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩147.32 Billion |
|
Markforged Holding Corp
NYSE:MKFG
|
USA | $82.41 Million |
|
Pasofino Gold Limited
V:VEIN
|
Canada | CA$28.51 Million |
|
Sukgyung AT Co. Ltd.
KQ:357550
|
Korea | ₩10.47 Billion |
|
Geodrill Limited
TO:GEO
|
Canada | CA$59.08 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Unicycive Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Unicycive Therapeutics Inc's balance sheet.
Liquidity & Leverage Metrics
Unicycive Therapeutics Inc Total Liabilities Ratios Explained
Unicycive Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Unicycive Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Unicycive Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Unicycive Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $18.94 Million | -21.86% |
| 2024-12-31 | $24.24 Million | +34.65% |
| 2023-12-31 | $18.00 Million | +448.11% |
| 2022-12-31 | $3.28 Million | +45.31% |
| 2021-12-31 | $2.26 Million | -21.39% |
| 2020-12-31 | $2.88 Million | +218.38% |
| 2019-12-31 | $903.00K | -26.88% |
| 2018-12-31 | $1.24 Million | -- |
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester deriv… Read more